| Literature DB >> 32758747 |
Mary Vermi Aizza Corpuz1, Antonio Buonerba2, Giovanni Vigliotta3, Tiziano Zarra4, Florencio Ballesteros5, Pietro Campiglia6, Vincenzo Belgiorno7, Gregory Korshin8, Vincenzo Naddeo9.
Abstract
This paper presents an updated and comprehensive review on the different methods used for detection and quantification of viruses in wastewater treatment systems. The analysis of viability of viruses in wastewater and sludge is another thrust of this review. Recent studies have mostly focused on determining the abundance and diversity of viruses in wastewater influents, in samples from primary, secondary, and tertiary treatment stages, and in final effluents. A few studies have also examined the occurrence and diversity of viruses in raw and digested sludge samples. Recent efforts to improve efficiency of virus detection and quantification methods in the complex wastewater and sludge matrices are highlighted in this review. A summary and a detailed comparison of the pre-treatment methods that have been utilized for wastewater and sludge samples are also presented. The role of metagenomics or sequencing analysis in monitoring wastewater systems to predict disease outbreaks, to conduct public health surveillance, to assess the efficiency of existing treatment systems in virus removal, and to re-evaluate current regulations regarding pathogenic viruses in wastewater is discussed in this paper. Challenges and future perspectives in the detection of viruses, including emerging and newly emerged viruses such as the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in wastewater systems are discussed in this review.Entities:
Keywords: Emerging viruses; SARS-CoV-2; Sequencing; Sludge; Virus concentration; Virus detection
Mesh:
Substances:
Year: 2020 PMID: 32758747 PMCID: PMC7368910 DOI: 10.1016/j.scitotenv.2020.140910
Source DB: PubMed Journal: Sci Total Environ ISSN: 0048-9697 Impact factor: 7.963
Occurrence and viability of viruses in wastewater and sludge.
| Virus | Concentration | Viability | ||||||
|---|---|---|---|---|---|---|---|---|
| (size; typology) | WWTP | Influent (genome copies/L) | Effluent (genome copies/L) | Sludge (genome copies/kg of dry solids) | Reference | Sample matrix | Number samples with infectious virus/total number of samples | Reference |
| HEV | Municipal | 7.80 × 103 to 5.80 × 108 | 4.00 × 103 to 1.00 × 104 | Effluent | 30/30 | |||
| RoV | Municipal | 1.00 × 101 to 6.31 × 104 | 1.01 × 103 to 4.47 × 106 | 8.00 × 103 to 8.00 × 105 | Effluent pre-UV | 3/51 | ||
| Effluent post-UV | 4/50 | |||||||
| Activated sludge | 3/12 | |||||||
| RoV-A | Hospital | 2.08 × 106 to 8.7 × 108 | 4.50 × 106 to 1.10 × 107 | – | ||||
| HAdV | Municipal | 5.00 × 104 to 3.30 × 1010 | 7.76 × 103 to 7.60 × 109 | 1.80 × 104 to | Effluent | 15/16 | ||
| 6/12 | ||||||||
| Secondary effluent | 4/12 | |||||||
| Effluent pre-UV | 16/51 | |||||||
| 8/12 | ||||||||
| Effluent post-UV | 10/50 | |||||||
| Activated sludge | 12/12 | |||||||
| Thickened sludge | 2/2 | |||||||
| Anaerobically digested sludge | 1/8 | |||||||
| Hospital | 1.70 × 105 to 2.30 × 107 | 6.60 × 104 to 2.90 × 106 | – | |||||
| NoV GI | Municipal | 1.90 × 109 to 9.30 × 109 | 1.55 × 103 to 2.00 × 109 | 5.00 × 107 | – | |||
| Nov GII | Municipal | 1.48 × 105 to 2.60 × 109 | 1.41 × 104 to 9.90 × 108 | 1.60 × 104 to | – | |||
| Hospital | 0.00 to | 3.20 × 104 to 9.60 × 107 | – | |||||
| HAV | Municipal | 1.20 × 105 to 8.90 × 105 | 1.70 × 105 to 3.80 × 105 | Activated sludge: | Effluent | 8/12 | ||
| Activated Sludge | 2/12 | |||||||
| EV | Municipal | 3.80 × 108 to 2.40 × 109 | 5.40 × 107 to 1.60 × 109 | 5.47 × 107 to | Effluent | 9/25 | ||
| Effluent Pre-UV | 17/51 | |||||||
| Effluent Post-UV | 7/50 | |||||||
| Thickened Sludge | 2/2 | |||||||
| Anaerobically Digested Sludge | 1/8 | |||||||
| JCPyV | Municipal | 8.33 × 104 to 3.20 × 108 | 1.00 × 106 to 1.00 × 108 | Zhang | ||||
| PMMV | Municipal Ponds | 3.16 × 106 to 1.00 × 109 | 6.31 × 104 to 1.52 × 108 | Effluent | Infectivity confirmed by inoculating effluent with test plants | |||
| HPyV | Municipal | 1.83 × 107 to 4.17 × 107 | 1.20 × 103 to 3.70 × 105 | 7.40 × 107 to | ||||
| Sapovirus | Municipal | 5.01 × 103 to 1.00 × 105 | 2.50 × 102 to 2.51 × 103 | |||||
| BK Polyomavirus | Municipal | 3.16 × 104 to 1.00 × 107 | 0.40 × 103 to 2.51 × 104 | |||||
| AiV | Municipal | 7.90 × 104 to 1.58 × 107 | 1.00 × 103 to 2.51 × 105 | |||||
| Parechovirus | Municipal | 2.51 × 107 to | Sludge | 1/307 | ||||
| Reovirus | Municipal | 2.10 × 103 to 3.00 × 104 | 1.70 × 106 to 3.72 × 106 | Effluent pre-UV | 47/51 | |||
| Effluent post-UV | 24/50 | |||||||
| Raw Sludge | 12/15 | |||||||
| Anaerobically digested sludge | 1/9 | |||||||
| SARS-CoV-1 | Hospital sewage | Hospital sewage seeded with virus | 1/1 | |||||
| Hospital sewage before disinfection with chlorine | 0/10 | |||||||
| SARS-CoV-2 | Municipal | 1.90 × 101 to 3.00 × 106 | 2.40 × 103 to | 1.25 × 104 to | Influent | 0/8 | ||
| Effluent | 0/4 | |||||||
| Hospital | 0.00 | 0.50 × 100 to | ||||||
Notes:
dsDNA, double-stranded DNA
ssRNA, single-stranded DNA
Reference for virus size and structure.
No available quantitative (concentration) or viability data of virus in specified sample matrix in previous studies.
Secondary Treatment Effluent.
Expressed in genome copies/L.
Before UV Treatment.
Fig. 1Occurrence of representative viruses in wastewater.
Methods of concentration of viruses in wastewater samples.
| Method | Sample Volume (L) | Advantages | Disadvantages | References |
|---|---|---|---|---|
| VIRADEL | 0.50–400 | Reduces amount of PCR inhibitors | Higher sample volume needed | |
| Ultrafiltration | 1–10 | May be used for simultaneous concentration of viruses and other microbes | Clogging of filters when sample is of high turbidity (except for tangential ultrafiltration) | |
| Centrifugal ultrafiltration | 0.01–0.10 | Lower sample volume needed | Small pore size may result to clogging of filters | |
| Precipitation with PEG | 0.40–1 | Higher efficiency in concentrating RNA viruses | Concentrates enzymatic inhibitors (PCR inhibitors) |
Detection and quantification of viruses in wastewater and sludge samples.a
| Wastewater sample | Viruses | Concentration/pre-treatment method | Nucleic acid extraction | Virus detection/quantification | Reference |
|---|---|---|---|---|---|
| Wastewater treatment samples: (a) Effluent of natural oxidizing pond | AiV Genotype B | Beef extract and AlCl3 method followed by precipitation with PEG | Automatic extractor NucliSENS® EasyMag™ | RT-PCR | |
| Raw sewage | Oncogenic viruses: | Elution with glycine | Automatic extractor NucliSENS® EasyMag™ | Combined multiplex PCR and bead-based Luminex technology | |
| Influent wastewater | HAdV | VIRADEL | QIAamp DNA Blood Mini Kit | Combined real time PCR (qPCR) and multiplex Luminex xMAP assay | |
| Combined wastewater; Graywater | HAdV | Ultrafiltration followed by elution with sodium polyphosphate solution | QIAamp DNA Blood Maxi Extraction Kit | (a) For HAdV: | |
| Influent wastewater | PV1 | Primary: Filtration with electropositive filter and elution with beef extract and glycine | – | – | |
| (a) Influent municipal wastewater; | HEV | (a) VIRADEL | QIAamp Viral RNA Mini Kit | RT-PCR | |
| Effluent | EV | Adsorption-elution method (Mg-method and Al-method) | ZR Viral RNA kit | RT-qPCR | |
| Hospital wastewater treatment plant samples: | RoV-A | Adsorption-elution using electronegative membrane | QIAamp Viral RNA Kit | (a) Conventional PCR, RT-PCR | |
| Municipal wastewater treatment samples: | NoV | Adsorption-elution using NanoCeram disc filters | MagaZorb total RNA Prep kit | qPCR | |
| Municipal wastewater treatment samples: | HAdV | (a) For Influent and Secondary Effluent: | QIAmp Viral RNA Mini Kit | RT-qPCR | |
| Wastewater treatment samples: | HAdV | Ultrafiltration | Qiagen DNeasy Blood and Tissue kit | qPCR | |
| Wastewater treatment samples: | NoV | Sludge samples: ASTM 4994-19 | AllPrep DNA/RNA Mini Kit | (a) For NoV, RoV, PMMV: | |
| Municipal wastewater treatment samples: | Virus type not determined (quantification only) | Elution with solutions | – | (a) Epifluorescence Microscopy (EFM) using SYBR Green I as stain | |
| Influent wastewater | HAdV | Concentration with Phosphate-buffered saline (PBS) solution | For qPCR: QIAamp Viral RNA mini Kit | (a) Immunofluorescence assay | |
| Influent wastewater | Virus type not determined (quantification only) | Ultrasonication | – | Flow cytometry (FCM) | |
| Activated sludge | Virus type not determined (quantification only) | Addition of dispersants Tween 80, sodium pyrophosphate, and sodium cholate; | – | Flow cytometry | |
| Activated sludge mixed liquor | Virus type not determined (quantification and determination of viral size distribution only) | Sonication | PFGE Method | PFGE | |
| Sludge samples (influent and effluent of anaerobic digesters) | Enteroviruses | Precipitation with PEG | Qiagen Viral RNA extraction kit | PCR; | |
| Sludge sewage samples | Enteric viruses | EVE | Sepa-gene RV-R | RT-PCR | |
| Sewage sludge samples | HAdV | Ultracentrifugation; | QIAamp Viral RNA Kit | RT-qPCR | |
| Primary sludge samples | EV | Beef Extract elution with sonication; | RNeasy plant mini kit | RT-PCR | |
| Raw sludge samples | Mammalian orthoreovirus | Adsorption elution; | QIAamp Viral RNA Kit | ICC-RT-qPCR; |
Note: aData for SARS-CoV-2 are reported in Table 4.
Detection and quantification of SARS-CoV-2 in wastewater and sludge.
| Reference; | Sample type; | Sample pre-treatment | Concentration method | PCR inhibitor treatment | RNA extraction | Concentration in genome copies/L | Viability test results, number samples with infectious virus/total number of samples | Detection/quantization/viability analysis methods | |
|---|---|---|---|---|---|---|---|---|---|
| Influent | Effluent | ||||||||
| Municipal wastewater; | Centrifugation | Centrifugal filtration (Centricon Plus-70, MWCO of 10 kDa) | – | RNeasy PowerMicrobe | RT-PCR: (one step) EvoScript RNA Probes Master (Roche); | ||||
| ( | Municipal wastewater; | Pasteurization | PEG/NaCl, centrifugation | – | TRIzol | 1.04 × 103 | RT-PCR | ||
| Municipal wastewater; | Filtration (5 μm and 0.45 μm pore size) | Centrifugal filtration (Corning Spin-X UF, MWCO of 100 kDa) | – | RNeasy Mini Kit (Qiagen) | 104 | RT-qPCR (one-step) TaqPath™ 1-Step RT-qPCR Master Mix, CG (ThermoFisher); | |||
| Municipal wastewater; | Filtration (0.45 μm pore size) | a. Electronegative membrane filtration (HAWP09000, Merk; pore size of 0.45 μm) | – | RNeasy PowerWater Kit; RNeasy PowerMicrobiome (Qiagen) | 1.90 × 101 to | RT-qPCR (one-step) iTaq™ Universal Probes One-Step Reaction Mix (Bio-Rad) | |||
| Municipal wastewater; | – | Ultracentrifugation | PCR Inhibitor removal resin (Zymo Research) | PowerFecal Pro kit with a QIAsymphony automated extractor (QIAGEN) | 5.00 × 104 to | RT-qPCR | |||
| Hospital sewage; | – | – | – | SARS-CoV-2 nucleic acid detection kit (Shanghai Berger Medical Technology Co., China) | 0/6 | RT-PCR; | |||
| ( | Municipal wastewater; | pH Adjustment at 6; | Precipitation with AlCl3, centrifugation; elution with beef extract (3%, pH 7.4), centrifugation and resuspension in PBS | – | Nucleospin RNA virus Kit (Macherey-Nagel) | 1.48 × 105 to | Secondary Effluent: | PrimeScript™ One Step RT-PCR Kit; | |
| Municipal wastewater; | Pasteurization | PEG-Dextran precipitation | One step PCR Inhibitor removal kit (Zymo Research) | NucliSENS miniMAG semi-automated extraction system (bioMerieux,) | RT-PCR | ||||
| Municipal wastewater; | Filtration (0.7 μm and 0.2 μm nominal pore size) | Not carried out | – | QIAMP VIRAL RNA mini kit (Qiagen, Hilden, Germany) | Influent: 0/8 | Real-Time RT-PCR | |||
| Municipal wastewater; | Centrifugation | a. PEG or alum precipitation, centrifugation, | – | RNA extraction kit (RNeasy mini kit- QIAGEN and EasyMAG-bioMerieux, France) | Only Cycle Treshold (Ct) numbers were given | Only Cycle Treshold (Ct) numbers were given | RT-qPCR | ||
| Municipal wastewater; | – | Electronegative membrane-vortex method; | – | RNeasy PowerWater Kit (Qiagen) | Not detected | 2.4 × 103 | RT-qPCR | ||
| Municipal wastewater; | Centrifugation | PEG 6000/NaCl precipitation | EZ1 virus Mini kit | Not detected | 0.5 × 103 to | RT-qPCR | |||
| ( | Municipal wastewater sludge; | Centrifugation; filtration (0.45 and 0.2 μm nominal pore size); pH Adjustment at 7.0–7.2 | PEG 8000/centrifugation | n.r. | Roche MagNA pure LC total nucleic acid isolation kit using Roche MagNA pure LC system (Penzberg, Germany) | Primary Sludge: | RT-qPCR | ||
| Municipal wastewater sludge; | Not carried out | Not carried out | n.r. | RNeasey PowerSoil Total RNA kit, Qiagen | Primary Sludge: | RT-qPCR | |||
Note: n.r. Not reported
No available quantitative (concentration) or viability data of virus in wastewater or sludge
Main primers and probes used in molecular detection and quantification of SARS-CoV-2 in wastewater.
| Study | Oligonucleotide name | Oligonucleotide Sequence | Target genes | Reference |
|---|---|---|---|---|
| N_Sarbeco_F | CACATTGGCACCCGCAATC | Nucleocapsid protein (N) | ( | |
| N_Sarbeco_R | GAGGAACGAGAAGAGGCTTG | |||
| N_Sarbeco_P | FAM-ACTTCCTCAAGGAACAACATTGCCA-BBQ | |||
| NIID_2019-nCOV_N_F2 | AAATTTTGGGGACCAGGAAC | Nucleocapsid protein (N) | ( | |
| NIID_2019-nCOV_N_R2 | TGGCAGCTGTGTAGGTCAAC | |||
| NIID_2019-nCOV_N_R2ver3 | TGGCACCTGTGTAGGTCAAC | |||
| NIID_2019-nCOV_N_P2 | FAM-ATGTCGCGCATTGGCATGGA-BHQ | |||
| 2274 - CO-FW1 | GTGCTAAACCACCGCCTG | ORF1ab | ( | |
| 2275 - CO-REV1 | CAGATCATGGTTGCTTTGTAGGT | |||
| 2276 - CO-FW2 | CGCCTGGAGATCAATTTAAACAC | |||
| 2277 - CO-REV2 | ACCTGTAAAACCCCATTGTTGA | |||
| WuhanCoV-spk1-f | TTGGCAAAATTCAAGACTCACTTT | Spike protein gene (S). | ( | |
| WuhanCoV-spk2-r | TGTGGTTCATAAAAATTCCTTTGTG | |||
| NIID_WH-1_F24381 | TCAAGACTCACTTTCTTCCAC | |||
| NIID_WH-1_R24873 | ATTTGAAACAAAGACACCTTCAC | |||
| RdRP_SARSr-F2 | GTGARATGGTCATGTGTGGCGG | RdRP gene | ( | |
| RdRp_SARSr-F | GTGARATGGTCATGTGTGGCG | RNA-dependent RNA polymerase gene (RdRp) | ( | |
| RdRp_SARSr-R | CARATGTTAAASACACTATTAGCATA | |||
| RdRP_SARSr-P1 | FAM-CCAGGTGGWACRTCATCMGGTGATGC-BBQ | ( | ||
| RdRp_SARSr-P2 | FAM-CAGGTGGAACCTCATCAGGAGATGC-BBQ | |||
| 2019-nCoV_N1-F | GACCCCAAAATCAGCGAAAT | Nucleocapsid protein (N) | Centers for Disease Control and Prevention, CDC (US 2020) | |
| 2019-nCoV_N1-R | TCTGGTTACTGCCAGTTGAATCTG | |||
| 2019-nCoV_N1-P | FAM-ACCCCGCATTACGTTTGGTGGACC-BHQ1 | |||
| 2019-nCoV_N2-F | TTACAAACATTGGCCGCAAA | |||
| 2019-nCoV_N2-F | GCGCGACATTCCGAAGAA | |||
| 2019-nCoV_N2-F | FAM-ACAATTTGCCCCCAGCGCTTCAG- BHQ1 | |||
| 2019-nCoV_N3-F | GGGAGCCTTGAATACACCAAAA | |||
| 2019-nCoV_N3-F | TGTAGCACGATTGCAGCATTG | |||
| 2019-nCoV_N3-F | FAM-AYCACATTGGCACCCGCAATCCTG- BHQ1 | |||
| E_Sarbeco_F | ACAGGTACGTTAATAGTTAATAGCGT | Envelope protein gene (E) | ( | |
| E_Sarbeco_R | ATATTGCAGCAGTACGCACACA | |||
| E_Sarbeco_P | FAM-ACACTAGCCATCCTTACTGCGCTTCG-BBQ | |||
| F. Wu et al., 2020 | S-RPA-Forward_v1 | GAAATTAATACGACTCACTATAGGGAGGT | Spike protein gene (S) | ( |
| S-RPA-Reverse_v1 | TCCTAGGTTGAAGATAACCCACATAATAAG | |||
| N1 forward and reverse | sequences not available | Nucleocapsid protein (N) | 2019-nCoV CDC EUA Kit-IDT#10006606 | |
| N2 forward and reverse | sequences not available | Nucleocapsid protein (N) | ||
| CCDC-ORF1, forward primer | CCCTGTGGGTTTTACACTTAA | ORFlab | Not indicated | |
| CCDC-N, forward primer | GGGGAACTTCTCCTGCTAGAAT | Nucleocapsid protein (N) | Not indicated | |
| N_Sarbeco_F1 | CACATTGGCACCCGCAATC | Nucleocapsid protein (N) | ( | |
| N_Sarbeco_R1 | GAGGAACGAGAAGAGGCTTG | |||
| N_Sarbeco_P1 | FAM-ACTTCCTCAAGGAACAACATTGCCA-BBQ | |||
| NIID_2019-nCOV_N_F2 | AAATTTTGGGGACCAGGAAC | Nucleocapsid protein (N) | ( | |
| NIID_2019-nCOV_N_R2ver3 | TGGCACCTGTGTAGGTCAAC | |||
| NIID_2019-nCOV_N_P2 | FAM-ATGTCGCGCATTGGCATGGA-BHQ1 | |||
| 2019-nCoV_N1-F | GACCCCAAAATCAGCGAAAT | Nucleocapsid protein (N) | Centers for Disease Control and Prevention, CDC (US 2020) | |
| 2019-nCoV_N1-R | TCTGGTTACTGCCAGTTGAATCTG | |||
| 2019-nCoV_N1-P | FAM-ACCCCGCATTACGTTTGGTGGACC-BHQ1 | |||
| 2019-nCoV_N2-F | TTACAAACATTGGCCGCAAA | |||
| 2019-nCoV_N2-F | GCGCGACATTCCGAAGAA |
Note: FAM: 6-carboxyfluorescein; BBQ: blackberry quencher; BHQ (and BHQ1): Black Hole Quencher 1
N1 and N2 primer sets only